Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189).

被引：2

作者：

Inwards, David James

Hillman, David. W.

Fishkin, Paul A.

White, William L.

Morton, Roscoe F.

Dakhil, Shaker R.

Nikcevich, Daniel A.

Wender, Donald B.

Fitch, Tom R.

Kurtin, Paul J.

机构：

[1] Mayo Clin, Coll Med, Rochester, MN USA

[2] Illinois Oncol Res Assoc, Peoria, IL USA

[3] Med Oncol & Hematol Associates, Des Moines, IA USA

[4] Witchita CCOP, Wichita, KS USA

[5] Duluth Clin, Duluth, MN USA

[6] Siouxland Reg Canc Ctr, Sioux City, IA USA

[7] Mayo Clin Scottsdale, Scottsdale, AZ USA

来源：

BLOOD | 2006年 / 108卷 / 11期

关键词：

D O I：

10.1182/blood.V108.11.2746.2746

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2746

引用

页码：777A / 777A

页数：1

共 50 条

[1] Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group
Inwards, David J.
Fishkin, Paul A. S.
Hillman, David W.
Brown, David W.
Ansell, Stephen M.
Kurtin, Paul J.
Fonseca, Rafael
Morton, Roscoe F.
Veeder, Michael H.
Witzig, Thomas E.
CANCER, 2008, 113 (01) : 108 - 116
[2] A Phase I/II Study of Vorinostat (SAHA), Cladribine (2-CdA), and Rituximab Shows Significant Activity in Previously Untreated Mantle Cell Lymphoma
Spurgeon, Stephen
Chen, Andy I.
Okada, Craig
Parekh, Samir
Leshchenko, Violetta V.
Palmbach, Gundula
Ratterree, Bashi
Subbiah, Nan
Capper, Christine
Epner, Elliot M.
BLOOD, 2011, 118 (21) : 203 - 203
[3] Cladribine (2-CDA) plus sequential rituximab in newly diagnosed disseminated extranodal marginal zone B-cell lymphormas. A phase II
Corazzelli, Gaetano
Capobianco, Gaetana
Russo, Filippo
Villani, Oreste
Vassallo, Patrizia
Pinto, Antonio
BLOOD, 2006, 108 (11) : 781A - 782A
[4] Cladribine plus rituximab is an effective therapy for newly diagnosed mantle cell lymphoma
Spurgeon, Stephen E.
Pindyck, Talia
Okada, Craig
Chen, Yiyi
Chen, Zunqiu
Mater, Elana
Abbi, Kamal
Epner, Elliot M.
LEUKEMIA & LYMPHOMA, 2011, 52 (08) : 1488 - 1494
[5] Targeting the epigenome: A phase I/II study of vorinostat (SAHA), cladribine (2-CdA), and rituximab in relapsed B-cell malignancies
Spurgeon, S. E.
Okada, C. Y.
Huang, J.
Phillips, J.
Epner, E. E.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
[6] A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).
Wang, Michael
Gordon, Leo I.
Rule, Simon
Goy, Andre
Hermine, Olivier
Rizo, Aleksandra
Zhuang, Sen Hong
Dreyling, Martin H.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[7] Phase II trial of cladribine (2-CDA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution
Bertazzoni, P.
Laszlo, D.
Gigli, F.
Bassi, S.
Calabrese, L.
Saronni, L.
Quama, J.
Alietti, A.
Cocorocchio, E.
Martinelli, G.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 390 - 390
[8] Phase II trial of cladribine (2-CdA) and rituximab in patients with CLL and SLL: Preliminary report of a single institution
Bertazzoni, P.
Laszlo, D.
Gigli, F.
Bassi, S.
Calabrese, L.
Saronni, L.
Quarna, J.
Alietti, A.
Cocorocchio, E.
Martinelli, G.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[9] Phase II trial of cladribine (2-CDA) and rituximab (R) in patients with Waldenstrom's macroglobulinemia (WM) or small lymphocytic lymphoma (SLL): Preliminary report of a multicenter study
Laszlo, D
Andreola, G
Rabascio, C
Mancuso, P
Balzano, R
Bassi, S
Bertazzoni, P
Antoniotti, P
Manz, C
Pinto, A
Billio, A
Martinelli, G
ANNALS OF ONCOLOGY, 2005, 16 : 112 - 112
[10] Phase 2 Open-Label Study of Bortezomib, Cladribine, and Rituximab in Advanced, Newly Diagnosed, and Relapsed/Refractory Mantle-Cell and Indolent Lymphomas
Puvvada, Soham D.
Guillen-Rodriguez, Jose
Kumar, Abhijeet
Inclan, Lora
Heard, Kara
Rivera, Xavier I.
Anwer, Faiz
Schatz, Jonathan H.
Mahadevan, Daruka
Persky, Daniel O.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01) : 58 - 64

← 1 2 3 4 5 →